Receiving CE certification for PREDICTIX Digital is an important milestone for Taliaz, and a major step forward in our continued expansion of our pioneering PREDICTIX technology into Europe and other new markets
European Union Horizon 2020 Grants are financial funding projects that encourage scientific innovation in Europe, specifically for projects which improve society. The grant was provided to Taliaz to help it expand its clinical research to Europe and further enhance mental health, specifically focusing on how its product can assist in combating, treating, and managing patient depression in several EU countries.
Since 2015, an Israeli start-up called Taliaz is overcoming this challenge. Neuroscientist Dr. Dekel Taliaz, together with his brother Oren, founded the company and gave it the siblings’ family name, Taliaz. Its mission is to empower doctors and patients with artificial intelligence to improve the assessment, management and prescribing success in mental health disorders. In other words, to support doctors to prescribe the right medication the first time and help minimize or remove today’s painful trial and error period.
Taliaz CEO Dr. Dekel Taliaz interviewed in Forbes. “We would be in a very different place if we had better access to up-to-date global medical insights”, he says. “Rather than decision makers relying on outdated or irrelevant statistics, they would have the power to make flexible decisions based on real-life conditions.”
With potentially millions of data points to analyze and consider, this is not something our brain is capable of – especially not in a standard 8-minute doctor-patient consultation. As a solution, Taliaz has combined AI with deep scientific-clinical evidence to develop smart tools that help doctors and the health system provide better care while saving time and money.
Speaking with ISRAEL21c, a leading American online magazine focused on technological and scientific advances made by researchers in Israel, Taliaz CEO, Dekel Taliaz shares his story on why he founded Taliaz with his brother, Oren.
Taliaz placed in the top 20% of all startups rated by Early Metrics. One of the main strengths we identified was the expertise behind the project: Dekel Taliaz, the CEO, has a PhD in Neurobiology and Behavior, in addition to experience conducting research on genetic mechanisms in mood disorders.
Only by combining deep scientific research, genetics, neurological, environmental and clinical data, can we understand these complexities and identify the relevant markers to build prediction models that can offer these patients the best outcome,” says Taliaz CEO Dekel Taliaz, who has a PhD in Neuroscience from the Weizmann Institute.
+972 (0)77 335 2506
2 Prof. Yehezkel Kaufmann St. Tel Aviv-Yafo, Israel
Let's help patients recover sooner with PREDICTIX